Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23744637 | 0.93 | CHRM4 (0.45) | HRH3CHRM4HCRTR1HCRTR2CHRM2 | |
| SCHEMBL23744735 | 0.92 | HRH3 (0.43) | HRH3CHRM4HCRTR1HCRTR2CHRM2 | |
| SCHEMBL26434902 | 0.90 | CHEK2 (0.46) | HRH3CHRM4HCRTR1HCRTR2 | |
| SCHEMBL26429699 | 0.88 | HCRTR1 (0.38) | HRH3CHRM4HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL23744472 | 0.86 | HRH3 (0.38) | HRH3CHRM4CYP3A4CYP2C9TSHR | |
| SCHEMBL23744655 | 0.83 | CHRM4 (0.47) | CHRM4CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL23744456 | 0.83 | CHRM4 (0.47) | CHRM4CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL23744206 | 0.82 | NPC1 (0.54) | CHRM4CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL23744256 | 0.82 | NPC1 (0.54) | CHRM4CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL26429662 | 0.82 | HCRTR1 (0.37) | HRH3CHRM4HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | HRH3 104/4885CHRM4 1/4885HCRTR1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.